Comorbidities in psoriasis


Cite item

Full Text

Abstract

The article describes the modern data on the connection of psoriasis with various comorbidities. It identifies the most frequent comorbid diseases recorded in patients, depending on the severity ofpsoriasis. Among the most common comorbidities, there are cardiovascular diseases, diabetes, metabolic syndrome, that must be considered when choosing the treatment.

About the authors

O. Yu Olisova

I.M. Sechenov First Moscow State Medical University

Кафедра кожных венерических болезней им. В.А. Рахманова Moscow, 119991, Russian Federation

Lusine G. Garanyan

I.M. Sechenov First Moscow State Medical University

Email: lusine90@list.ru
Department of Dermatology and Venereology of I.M. Sechenov First Moscow State Medical University Moscow, 119991, Russian Federation

References

  1. Esposito M., Saraceno R., Giunta A., Maccarone M., Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006; 12(2): 123-7.
  2. Augustin M., Reich K., Glaeske G., Schaefer I., Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta dermato-venereologica. 2010; 90(2): 147-51.
  3. Дегтярев О.В., Меснянкина О.А. Патогенетическая роль нарушений липидного профиля при псориазе. Российский журнал кожных и венерических болезней. 2015; 18 (1): 30-3.
  4. Кочергин Н.Г., Смирнова Л.М., Потекаев Н.Н, Билалова У.Г.Псориаз: коморбидности и комедикации. Врач. 2009; (5): 15-20.
  5. Li K., Armstrong A.W. A review of health outcomes in patients with psoriasis. Dermatol. Clin. 2012; 30(1): 61-72. doi: 10.1016/j.det.2011.08.012.
  6. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность. Клиническая медицина. 2012; (10): 4-11.
  7. Смирнова Л. М., Билалова У. Г. Метаболический синдром и псориаз. М.: ФМК НАДК; 2009.
  8. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14): 1735-41.
  9. Ryan C., Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol. Clin. 2015; 33(1): 41-55.
  10. Gelfand J.M., Troxel A.B., Lewis J.D., Kurd S.K., Shin D.B., Wang X., et al. The risk of mortality in patients with psoriasis: results from a populationbased study. Arch. Dermatol. 2007; 143(12): 1493-9.
  11. Mallbris L., Akre O., Granath F., Yin L., Lindelöf B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur. J. Epidemiol. 2004; 19(3): 225-30.
  12. Kaye J.A., Li L., Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br. J. Dermatol. 2008; 159(4): 895-902.
  13. Abuabara K., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br. J. Dermatol. 2010; 163(3): 586-92. doi: 10.1111/j.1365-2133.2010.09941.x.
  14. Kimball A.B., Robinson D.Jr., Wu Y., Guzzo C., Yeilding N., Paramore C., et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology. 2008; 217(1): 27-37. doi: 10.1159/000121333.
  15. Armstrong E.J., Harskamp C.T., Armstrong A.W. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J. Am. Heart Assoc. 2013; 2(2): e000062. doi: 10.1161/JAHA.113.000062.
  16. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005; 365(9468): 1415-28.
  17. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006; 298(7): 321-8.
  18. Лыкова С.Г. Некоторые аспекты взаимосвязи псориаза и метаболического синдрома. Российский журнал кожных и венерических болезней. 2003; (4): 34-8.
  19. Langan S.M., Seminara N.M., Shin D.B., Troxel A.B., Kimmel S.E., Mehta N.N., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J. Invest. Dermatol. 2012; 132(3): 556-62.
  20. Goldminz A.M., Buzney C.D., Kim N., Au S.C., Levine D.E., Wang A.C., et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr. Dermatol. 2013; 30(6): 700-5. doi: 10.1111/pde.12218.
  21. Wu S., Li W.Q., Han J., Sun Q., Qureshi A.A. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arth. Rheumatol. 2014; 66(2): 304-10. doi: 10.1002/art.38227.
  22. Yu Y., Sheth N., Krishnamoorthy P., Saboury B., Raper A., Baer A., et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am. J. Cardiovasc Dis. 2012; 2(4): 285-92.
  23. Mehta N.N., Li R., Krishnamoorthy P., Yu Y., Farver W., Rodrigues A. et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012; 224(1): 218-21.
  24. Holzer M., Wolf P., Inzinger M., Trieb M., Curcic S., Pasterk L., et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J. Invest. Dermatol. 2014; 134(3): 635-42.
  25. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013; 149(1): 84-91.
  26. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006; 55(5): 829-35.
  27. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch. Inter. Med. 2007; 167(15): 1670-5.
  28. Mallbris L., Granath F., Hamsten A., Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 2006; 54(4): 614-21.
  29. Herron M.D., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., Krueger G.G. Impact of obesity and smoking on psoriasis presentation and management. Arch. Dermatol. 2005; 141(12): 1527-34.
  30. Paller A. S., Mercy K., Kwasny M.J., Choon S.E., Cordoro K.M., Girolomoni G., et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013; 149(2): 166-76.
  31. Friedewald V.E., Cather J.C., Gelfand J.M., Gordon K.B., Gibbons G.H., Grundy S.M., et al. AJC editors consensus: psoriasis and coronary artery disease. Am. J. Cardiol. 2008; 102(12): 1631-43.
  32. Strohal R., Kirby B., Puig L.; Psoriasis Expert Panel; Girolomoni G., Kragballe K., Luger T., et al. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 2014; 28(12): 1661-9. doi: 10.1111/jdv.12350.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies